Level C· Early human research exploring benefitsProspective StudyPubMed

Type 2 diabetes mellitus limits the glucose-responsive β-like functionality but not pancreatic lineage commitment of induced human adipose-derived stem cells.

Mohamed NA., Salem AMH., El-Erian AM., Mahmoud M., Ahmed AE., Hozayen WG.

Prospective Study on Type 2 Diabetes, published in Int J Biochem Cell Biol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Int J Biochem Cell Biol (2026)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
42562078
DOI
10.1016/j.biocel.2026.107003

Abstract (original English)

Background Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases, whose prevalence is increasing worldwide. There is a great demand for an effective cure that attains a normal glucose level. The differentiation of mesenchymal stem cells into insulin-producing cells (IPCs) for pancreatic regeneration represents a promising anti-diabetic therapeutic approach. However, the pathogenic milieu of T2DM may affect their differentiation potential. Aim This study aimed to investigate the impact of the T2DM milieu on the pancreatic differentiation potential of human adipose-derived stem cells (ASCs) in vitro. Methods We isolated and cultured ASCs from T2DM (dASCs) and non-diabetic (nASCs) subjects, then we differentiated the cells into IPCs. We evaluated the differentiation potential using dithizone staining, immunofluorescence staining, and gene expression analysis. We examined the functionality of generated cells via glucose challenge assay. Results Our results revealed that both dASCS and nASCs could be committed to an early endocrine-like phenotype with comparable potential. However, the glucose-stimulated insulin secretion of dASCs-derived IPCs was significantly less than that derived from nASCs. Conclusion T2DM does not affect the pancreatic commitment potential of dASCs. However, ASCs-derived from diabetic patients displayed a reduced capacity to acquire glucos

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research